Characteristic Study ID	Endpoint	Time of measurementa	Outcome reportingb [analysed & reported as not significant (e.g. P > 0.05)]	Outcome reportingb [analysed but not reported]	Outcome reportingb [measured & not analysed or analysed but not reported because of non‐significant results ]	Outcome reportingb [not mentioned but likely to have been measured & analysed but not reported because of non‐significant results]
Kaats 1996	Body composition improvement (P)	0, 72 days	N/A	N/A	N/A	N/A
	Body weight (P)	0, 72 days	x	N/A	N/A	N/A
	Fat weight (P)	0, 72 days	N/A	N/A	N/A	N/A
	Percentage body fat (S)	0, 72 days	N/A	N/A	N/A	N/A
	Non‐fat mass (S)	0, 72 days	x	N/A	N/A	N/A
Kaats 1998	Body weight (P)	0, 90 days	N/A	N/A	N/A	N/A
	Fat weight (P)	0, 90 days	N/A	N/A	N/A	N/A
	Percentage body fat (S)	0, 90 days	N/A	N/A	N/A	N/A
	Fat‐free mass (S)	0, 90 days	x	N/A	N/A	N/A
Joseph 1999	Fasting glucose (P)	1, 13 weeks	N/A	N/A	N/A	N/A
	Fasting insulin (P)	1, 13 weeks	x	N/A	N/A	N/A
	Fasting C‐peptide (S)	1, 13 weeks	x	N/A	N/A	N/A
	Weight loss (S)	1, 13 weeks	N/A	N/A	N/A	N/A
	BMI (S)	1, 13 weeks	x	N/A	N/A	N/A
	Waist circumference (S)	1, 13 weeks	x	N/A	N/A	N/A
	Waist to hip ratio (O)	1, 13 weeks	x	N/A	N/A	N/A
Kleefstra 2006	A1c (P)	0, 1, 3, 6 months	x	N/A	N/A	N/A
	Lipid profile (S)	0, 1, 3, 6 months	x	N/A	N/A	N/A
	BMI (S)	0, 1, 3, 6 months	x	N/A	N/A	N/A
	Blood pressure (S)	0, 1, 3, 6 months	x	N/A	N/A	N/A
	Plasma chromium concentration (S)	0, 1, 3, 6 months	x	N/A	N/A	N/A
Iqbal 2009	Insulin sensitivity index (P)	0, 16 weeks	x	N/A	N/A	N/A
	Glucose metabolism (S)	0, 16 weeks	N/A	N/A	N/A	N/A
	Oxidative stress (S)	0, 16 weeks	x	N/A	N/A	N/A
	Fasting serum lipids (S)	0, 16 weeks	x	N/A	N/A	N/A
	C‐reactive protein (S)	0, 16 weeks	x	N/A	N/A	N/A
	Weight (O)	0, 16 weeks	x	N/A	N/A	N/A
	Waist circumference (O)	0, 16 weeks	x	N/A	N/A	N/A
Volpe 2001	Percentage body fat (P)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Fat mass (P)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	BMI (P)	0, 6, 12 weeks	x	N/A	N/A	N/A
	Body weight (P)	0, 6, 12 weeks	x	N/A	N/A	N/A
	Resting metabolic rate (P)	0, 6, 12 weeks	x	N/A	N/A	N/A
	Biochemical parameters (S)	0, 6, 12 weeks	x	N/A	N/A	N/A
Anton 2008	Food intake (P)	0, 1, 8 weeks	N/A	N/A	N/A	N/A
	Hunger levels (P)	0, 1, 8 weeks	N/A	N/A	N/A	N/A
	Adverse events (P)	0, 1, 8 weeks	N/A	N/A	N/A	N/A
	Body weight (S)	0, 1, 8 weeks	N/A	N/A	N/A	N/A
	Fat cravings (S)	0, 1, 8 weeks	N/A	N/A	N/A	N/A
	Glucose and insulin (O)	0, 1, 8 weeks	x	N/A	N/A	N/A
Campbell 1999	Fat‐free mass (P)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Body weight (P)	0, 6, 12 weeks	x	N/A	N/A	N/A
	Urinary creatinine excretion (P)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Total body water (P)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Body muscle mass (P)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Vastus lateralis type II fibre area (S)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Skinfold thickness (S)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Resting metabolic rate (S)	0, 6, 12 weeks	x	N/A	N/A	N/A
	Percentage body fat (S)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
	Fat mass (S)	0, 6, 12 weeks	N/A	N/A	N/A	N/A
Yazaki 2010	BMI (P)	0, 12, 24 weeks	x	N/A	N/A	N/A
	Waist to hip ratio (P)	0, 12, 24 weeks	x	N/A	N/A	N/A
	Percentage body fat (S)	0, 12, 24 weeks	x	N/A	N/A	N/A
	Blood pressure (S)	0, 12, 24 weeks	x	N/A	N/A	N/A
	Basic metabolic (S)	0, 12, 24 weeks	x	N/A	N/A	N/A
	Urinalysis (O)	0, 12, 24 weeks	x	N/A	N/A	N/A
Footnotes: "‐" denotes not reported "x" denotes "yes" aUnderlined times of measurement denote data as reported in the results section of the publication (other times represent planned but not reported points in time) bConstitutes 'high risk of bias' according to the Outcome Reporting Bias In Trials (ORBIT) study classification system for missing or incomplete outcome reporting in reports of randomised trials (Kirkham 2010) (P) primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes which were not specified as 'primary' or 'secondary' outcomes in the publication Endpoint in bold = review primary outcome A1c: HbA1c (glycosylated haemoglobin A1c); BMI: body mass index; N/A: not applicable